Altium Capital Management LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Altium Capital Management LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 95,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,860,000. Altium Capital Management LLC owned 0.06% of TG Therapeutics as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TGTX. Arizona State Retirement System raised its stake in shares of TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. increased its position in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 371 shares during the period. Summit Investment Advisors Inc. lifted its holdings in shares of TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $440,000 after buying an additional 463 shares in the last quarter. Brookstone Capital Management boosted its position in shares of TG Therapeutics by 3.7% in the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 624 shares during the period. Finally, Daymark Wealth Partners LLC grew its stake in TG Therapeutics by 1.7% during the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock valued at $1,249,000 after acquiring an additional 689 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TGTX. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $38.32 on Friday. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The company has a fifty day moving average of $36.20 and a 200-day moving average of $31.74. The company has a market capitalization of $6.02 billion, a P/E ratio of -383.16 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.